- Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
- Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Vaccinex Reports 2023 Financial Results and Provides Corporate Update
- Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
- Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
- Vaccinex, Inc. Announces Reverse Stock Split
- Vaccinex Announces Pricing of $3.7 Million PIPE Financing
- Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
- Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Vaccinex Reports Clinical Benefit in Interim Analyses from two Phase 2 Studies of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual Meeting
More ▼
Key statistics
On Friday, Vaccinex Inc (VCNX:NAQ) closed at 7.43, 67.64% above the 52 week low of 4.43 set on Apr 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.01 |
---|---|
High | 7.80 |
Low | 7.00 |
Bid | 7.02 |
Offer | 7.47 |
Previous close | 6.90 |
Average volume | 66.95k |
---|---|
Shares outstanding | 1.58m |
Free float | 1.46m |
P/E (TTM) | -- |
Market cap | 11.36m USD |
EPS (TTM) | -46.02 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼